• SELECT SITE CURRENCY
Select a currency for use throughout the site
Qatar Pharmaceuticals and Healthcare Report Q3 2012
Business Monitor International, June 2012, Pages: 85
The Qatar Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Qatar's pharmaceuticals and healthcare industry.
BMI View: Unlike other countries in the Middle East that have focused on encouraging pharmaceutical companies to establish manufacturing facilities, Qatar’s focus is on education and research. As the country lacks the freight and shipping infrastructure of the UAE it makes sense that it is not trying to compete in this area. Qatar lacks the domestic market to attract much investment but the government’s programme of investment has created the environment for high-value innovation.
Headline Expenditure Projections
- Pharmaceuticals: QAR1.42bn (US$390mn) in 2011 to QAR1.55bn (US$426mn) in 2012; +9.1% in local currency and US dollar terms.
- Healthcare: QAR10.49bn (US$2.88bn) in 2011 to QAR11.51bn (US$3.16bn) in 2012; +9.8% in local currency and US dollar terms. Historic data down on Q212 but forecast growth rate has been increased.
- Medical devices: QAR1.02mn (US$279mn) in 2011 to QAR1.18mn (US$325mn) in 2012; +16.4% in local currency and US dollar terms.
Risk/Reward Rating: In BMI’s Q212 Risk/Reward Ratings (RRRs) for the Middle East and Africa (MEA) region, Qatar fell one place to fourth most attractive market out of the 30 countries assessed. Only the UAE scored higher for the risks category, which demonstrates Qatar’s favourable market and country structure, including a predictable operating environment and a sound economic base. On the other hand, its score for the rewards category is dragged down by a small and a relatively young population, despite high per capita spending on pharmaceuticals.
Key Trends And Developments
- The Sidra Medical and Research Centre is supposed to be completed by the end of 2012. The hospital will include 388 beds, with infrastructure to enable expansion to 550 beds in subsequent phases and it will specialise in paediatric care. The purpose of the facility is not solely to be a healthcare facility; it will also be a world-class education and biotechnology research centre. This is how it can justify its enormous price tag, as Sidra as been funded by a US$7.9bn endowment from the Qatar Foundation, the largest such payment for a medical and research centre anywhere in the world. The building construction contract alone was worth US$2.3bn.
- In February 2012, the respective Gulf Co-operation Council (GCC) authorities announced that they are looking to introduce a pan-regional IT system that will link the medical records of prospective workers and expatriates from 11 ‘labour exporting countries’ to the GCC Health Ministers’ Secretariat and to the ministries of health of the member states. This is part of the regional drive towards better integrating health information systems (HISs) to improve the quality and efficiency of patient care.
- The Qatari German Company for Medical Devices (QGMD) more than tripled its net losses to QAR1.81mn in the first three months of 2012, mainly on higher costs. Sales were QAR1.66mn, whereas cost of sales stood at QAR2.13mn; thereby leading to a gross loss of QAR0.47mn, according to the financial statement.
BMI Economic View: We see Qatar’s economy growing robustly in 2012. Although hydrocarbon exports will slow, heavy government spending is likely to spur growth in private consumption and fixed investments. We are forecasting real GDP growth of 7.9% and 6.9% in 2012 and 2013 respectively.
BMI Political View: Qatar’s increasing role in MENA affairs raises risks that the country will become increasingly exposed to regional tensions. The country has risen to prominence for its assertive foreign policy since the outbreak of the Arab Spring. Through its leadership within the Arab League and the GCC, and direct military intervention in Libya, Qatar has emerged as a regional powerhouse and is widely acknowledged for its support of political reforms across the MENA region.
Executive Summary 5
SWOT Analysis 7
Qatar Pharmaceuticals And Healthcare Industry SWOT 7
Qatar Political SWOT 8
Qatar Economic SWOT 9
Qatar Business Environment SWOT 9
Pharmaceutical Risk/Reward Ratings 10
Table: Middle East And Africa Pharmaceutical Risk/Reward Ratings, Q312 11
Qatar – Market Summary 17
Regulatory Regime 19
Regional Regulatory Developments 20
Intellectual Property Regime 22
Pricing And Reimbursement Regime 23
Industry Developments 25
Non-Communicable Diseases 26
Communicable Diseases 29
Healthcare Sector 30
Healthcare Sector Developments 34
Healthcare Reform 34
Health Insurance 36
Healthcare IT 36
Research & Development 38
Medical Devices Industry 39
Industry Forecast Scenario 41
Overall Market Forecast 41
Table: Pharmaceutical Sales Indicators 2008-2016 43
Key Growth Factors – Industry 44
Table: Healthcare Expenditure Indicators 2008-2016 45
Table: Government Healthcare Indicators 2008-2016 46
Table: Private Healthcare Indicators 2008-2016 46
Key Growth Factors – Macroeconomic 47
Table: Qatar Economic Activity, 2011-2016 50
Prescription Drug Market Forecast 51
Table: Prescription Drug Sales Indicators 2008-2016 52
Patented Drug Market Forecast 53
Table: Patented Drug Market Indicators 2008-2016 54
Generic Drug Market Forecast 55
Table: Generic Drug Sales Indicators 2008-2016 56
OTC Medicine Market Forecast 57
Table: OTC Medicine Sales Indicators 2008-2016 58
Medical Device Market Forecast 59
Table: Medical Devices Sales Indicators 2008-2016 60
Pharmaceutical Trade Forecast 61
Table: Exports and Imports Indicators, 2008-2016 62
Other Healthcare Data Forecasts 63
Key Risks To BMI’s Forecasts 64
Competitive Landscape 65
Pharmaceutical Industry 65
Pharmacy Wholesale And Retail 66
Company Profiles 67
Local Companies 67
Qatari German Company For Medical Devices (QGMD) 67
Medicare Group 69
Ebn Sina Medical 70
Multinational Companies 71
Merck & Co 72
Demographic Outlook 75
Table: Population By Age Group, 1990-2020 (‘000) 76
Table: Population By Age Group, 1990-2020 (% of total) 77
Table: Key Population Ratios, 1990-2020 78
Table: Rural And Urban Population, 1990-2020 78
BMI Methodology 81
How We Generate Our Pharmaceutical Industry Forecasts 81
Pharmaceutical Risk/Reward Ratings Methodology 82
Ratings Overview 82
Table: Pharmaceutical Risk/Reward Indicators 83
Table: Weighting Of Components 84